Corticosteroids

Eric Bywaters a life story: 1 June 1910 to 2 April 2003
David Isenberg

Annals of the Rheumatic Diseases Aug 2020, 79 (8) 996-998; DOI: 10.1136/annrheumdis-2020-217153
Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA. Response to: ‘Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone’ by Samson and Bonnotte
Christoph T Berger, Thomas Daikeler

Annals of the Rheumatic Diseases Aug 2020, 79 (8) e103; DOI: 10.1136/annrheumdis-2019-215729
Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy
Mary Safy-Khan, Johannes W G Jacobs, Maria J H de Hair, Paco M J Welsing, Michael D Edwardes, Xavier M Teitsma, Yves Luder, Jenny Devenport, Jacob M van Laar, Attila Pethoe-Schramm, Johannes W J Bijlsma

Annals of the Rheumatic Diseases Apr 2020, 79 (4) 460-463; DOI: 10.1136/annrheumdis-2019-216537
Dupilumab as a novel steroid-sparing treatment for IgG4-related disease
Rachel S Simpson, Stephanie Ka Ching Lau, Jason Kihyuk Lee

Annals of the Rheumatic Diseases Apr 2020, 79 (4) 549-550; DOI: 10.1136/annrheumdis-2019-216368
Comments on the article: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial”
Mohammad Reza Mousavi, Erfan Taherifard

Annals of the Rheumatic Diseases Mar 2020, annrheumdis-2020-217287; DOI: 10.1136/annrheumdis-2020-217287
A second case of dupilumab for the treatment of IgG4-related disease. Response to: ‘Comment on article: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al’ by Ebbo et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Mar 2020, annrheumdis-2020-217029; DOI: 10.1136/annrheumdis-2020-217029
Glucocorticoid withdrawal in lupus – to do or not to do?
Nupoor Acharya

Annals of the Rheumatic Diseases Mar 2020, annrheumdis-2020-217261; DOI: 10.1136/annrheumdis-2020-217261
Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial
Alexis Mathian, Micheline Pha, Julien Haroche, Fleur Cohen-Aubart, Miguel Hié, Marc Pineton de Chambrun, Thi Huong Du Boutin, Makoto Miyara, Guy Gorochov, Hans Yssel, Patrick Cherin, Hervé Devilliers, Zahir Amoura

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 339-346; DOI: 10.1136/annrheumdis-2019-216303
LACC1 gene mutation in three sisters with polyarthritis without systemic features
Ankita Singh, Deepti Suri, Pandiarajan Vignesh, Gummadi Anjani, Prince Jacob, Katta M Girisha

Annals of the Rheumatic Diseases Mar 2020, 79 (3) 425-426; DOI: 10.1136/annrheumdis-2019-216263
Response to: ‘Dupilumab as a potential steroid-sparing treatment for IgG4-related disease’ by Della-Torre et al
Rachel S Simpson, Jason K Lee

Annals of the Rheumatic Diseases Feb 2020, annrheumdis-2020-216955; DOI: 10.1136/annrheumdis-2020-216955

Main menu

Corticosteroids

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Corticosteroids

Pages